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Abstract
Background: We aimed to assess if quantitative radiomic features can predict
programmed death ligand 1 (PD-L1) expression in advanced stage lung
adenocarcinoma.
Methods: This retrospective study included 153 patients who had advanced
stage (>IIIA by TNM classification) lung adenocarcinoma with pretreatment thin
section computed tomography (CT) images and PD-L1 expression test results in
their pathology reports. Clinicopathological data were collected from electronic
medical records. Visual analysis and radiomic feature extraction of the tumor
from pretreatment CT were performed. We constructed two models for multi-
variate logistic regression analysis (one based on clinical variables, and the other
based on a combination of clinical variables and radiomic features), and com-
pared c-statistics of the receiver operating characteristic curves of each model to
identify the model with the higher predictability.
Results: Among 153 patients, 53 patients were classified as PD-L1 positive and
100 patients as PD-L1 negative. There was no significant difference in clinical char-
acteristics or imaging findings on visual analysis between the two groups (P > 0.05
for all). Rad-score by radiomic analysis was higher in the PD-L1 positive group than
in the PD-L1 negative group with a statistical significance (−0.378  1.537
vs. −1.171  0.822, P = 0.0008). A prediction model that uses clinical variables and
CT radiomic features showed higher performance compared to a prediction model
that uses clinical variables only (c-statistic = 0.646 vs. 0.550, P = 0.0299).
Conclusions: Quantitative CT radiomic features can predict PD-L1 expression in
advanced stage lung adenocarcinoma. A prediction model composed of clinical vari-
ables and CT radiomic features may facilitate noninvasive assessment of PD-L1
expression.
Key points: Significant findings of the study
Quantitative CT radiomic features can help predict PD-L1 expression, whereas
none of the qualitative imaging findings is associated with PD-L1 positivity.
What this study adds
A prediction model composed of clinical variables and CT radiomic features may
facilitate noninvasive assessment of PD-L1 expression.
Introduction
Lung cancer is the leading cause of cancer-related deaths
worldwide, and adenocarcinoma is the most common
histologic type of lung cancer.1,2 In the past, platinum-
based conventional chemotherapy was the only option
for treating advanced lung adenocarcinoma. However,
recent developments in molecular-targeted therapy has
significantly improved survival to subsets of patients
who are positive for genetic alteration such as mutation
in the epidermal growth factor receptor (EGFR) gene
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and rearrangement of the anaplastic lymphoma kinase
gene locus.3,4
Recently, immune checkpoint inhibitors targeting
programmed cell death protein 1 (PD-1) or programmed
death ligand 1 (PD-L1) have demonstrated better progression-
free and overall survival than conventional chemotherapy in
advanced non-small cell lung cancer (NSCLC) patients.5–7 As
immunotherapy became one of the standard treatment regi-
mens for NSCLC, biomarkers for predicting responses to
immune checkpoint inhibitors were investigated and PD-L1
expression on tumor cells was accepted as a predictive bio-
marker for the immunotherapy response.8–10 In this context,
the International Association for the Study of Lung Cancer
(IASLC) provided an atlas of PD-L1 immunohistochemistry
testing in NSCLC.11
The prediction of PD-L1 expression from computed
tomography (CT) imaging features may have value, not only
for predicting patient outcome by imaging, but also in situa-
tions where tissue sampling is not possible. Previous studies
have investigated the relationship between CT image fea-
tures and PD-L1 expression.12,13 However, these studies
focused primarily on qualitative imaging features with study
populations that were limited to early stage, resectable lung
adenocarcinomas; therefore, quantitative analysis may be
more valuable. “Radiomics,” an emerging tool that provides
quantitative imaging parameters, has been applied in oncol-
ogy for tumor assessment and evaluation of the patient’s
response to treatment (e.g. prediction of EGFR mutation
and response to the targeted therapy in NSCLC).14–19
Because a radiomics approach can provide objective and
quantitative parameters of the tumor, we hypothesized that
quantitative radiomic features can predict PD-L1 expression
in advanced stage lung adenocarcinoma.
Therefore, the purpose of this study was to assess if
quantitative radiomic features can predict PD-L1 expres-
sion in advanced stage lung adenocarcinoma.
Methods
Patients
Our institutional review board approved this retrospective
study, and the requirement for obtaining informed consent
was waived. We conducted a retrospective chart review, and
identified 169 patients who were diagnosed with lung adeno-
carcinomas from January 2016 to August 2018 and whose
pathological reports included a PD-L1 expression test result
obtained by tumor proportion score (TPS). Among these
169 patients, 16 patients were excluded from this study for
the following reasons: (i) a resectable stage of NSCLC (≤stage
IIIA by TNM classification according to the eighth edition of
IASLC)20 (n = 8); (ii) unavailability of thin section CT images
prior to treatment (n = 3); and (iii) indistinguishable primary
lesion in CT scan due to parenchymal collapse (n = 5). A
total of 153 patients were included in the study who were
diagnosed in pathological reports as having advanced stage
lung adenocarcinoma and having a PD-L1 expression test
result obtained by TPS (99 men, mean age 64.6  10.7 years,
range, 34–86 years) (Fig 1).
Clinicopathological data collected for each patient
included age, gender, smoking history, TNM stage, PD-L1
expression status by TPS, and EGFR mutation status.
Chest computed tomography
(CT) examinations
For all patients, contrast-enhanced chest CT scans were per-
formed by using one of following multidetector row scanners:
Somatom Sensation 16, Somatom Sensation 64, Definition
Flash (Siemens Medical Solutions, Forchheim, Germany),
Discovery CT 750 HD, Revolution (GE Medical Systems, Mil-
waukee, Wisconsin, USA), or iCT (Philips Medical Systems,
the Netherlands). Details of scanning parameters were the
same as previously described.21 A bolus of 50–90 mL (1.5
mL/kg bodyweight) of iopamidol (300 mg I/mL, Radisense,
Taejoon Pharmaceutical, Seoul, South Korea) was injected
intravenously at a flow rate of 3 mL/second for enhanced
images, and an automated bolus-tracking technique was used.
Axial and coronal images were reconstructed with soft tissue
kernel and a slice thickness of 1–1.25 mm and 2.5–3 mm,
respectively. All CT datasets were transferred to a picture
archiving and communication system.
Visual analysis of CT images
Visual analysis was performed by two board-certified tho-
racic radiologists (with nine and 10 years’ experience in chest
CT imaging, respectively) who were blinded to the clinical
and histologic findings. Two radiologists independently
reviewed all CT images, and any discrepancies in evaluations
were resolved by agreement. CT images were read on the
axial and coronal views with both mediastinal (width,
350 HU; level, 40 HU) and lung (width, 1500 HU; level,
−500 HU) window settings. CT image features that were
included in the visual analysis were as follows22,23: (i) size
(maximal and minimal diameters), location, type (nodule,
mass, multicentric, or ground-glass opacity [GGO]/consoli-
dation), and margin (lobulation, concavity, spiculation) of
primary mass; (ii) internal characteristics of tumor: presence
of internal calcification, air bronchogram, bubble-like
lucency, cavitation, or necrosis; (iii) external characteristics
of tumor: fissural or pleural attachment, thickening of adja-
cent bronchovascular bundles, pleural retraction, or periph-
eral emphysema; and (iv) associated findings: pattern of lung
metastasis, presence of pleural effusion, pleural nodularity,
significant pericardial effusion (moderate to large amount
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[>10 mm in depth] or pericardial nodularity or enhancement
regardless of size), intrathoracic bony metastases, or meta-
static lymphadenopathy.
CT radiomic feature extraction
Radiomic feature extraction was performed semi-
automatically by two radiologists (one radiology resident and
one board-certificated thoracic radiologist with 2 and
10 years’ experience in chest CT imaging, respectively). Digi-
tal Imaging and Communications in Medicine (DICOM)
files were loaded into a commercialized software (AVIEW
Research, Coreline Soft Inc., Seoul, South Korea) and lesion
segmentation was performed using a lung window setting
(width, 1500 HU; level, -600 HU) images (Fig 2). Using the
software, the volume of interest (VOI) was delineated around
the tumor outline slice by slice on the axial CT images as fol-
lows: After importing DICOM files into the software, we
used brush tools to manually delineate the VOI slice by slice
at the voxel level. Image magnification and three-
dimensional view techniques were used to facilitate precise
segmentation. Large vessels and bronchioles were excluded
from the VOIs where possible. From a segmented VOI, a
total of 58 radiomic features were extracted: 15 histogram
features, two gradient features, 13 gray-level co-occurrence
matrix (GLCM) features, 13 gray-level run-length matrix
(GLRLM) features, three moment features, 11 shape features,
and one fractal features (Table S1).
PD-L1 analysis method
Expression of PD-L1 in histopathologic specimens was
determined using the PD-L1 22C3 pharmDx antibody
(Dako North America Inc., Carpinteria, CA, USA) or Ven-
tana PD-L1 SP263 antibody (Ventana Medical Systems,
Tucson, AZ, USA) as a companion diagnosis. Positive
tumor cells were defined as complete circumferential or
partial cell membrane staining. Cytoplasmic staining and
tumor-associated immune cells (such as macrophages) were
excluded from the scoring. Finally, TPS was calculated as a
percentage of PD-L1-positive tumor cells relative to the
total tumor cells. We defined “PD-L1 expression positive”
as 50% or more viable tumor cells exhibiting membrane
staining with any intensity (TPS ≥50%).24,25 The 74 enrolled
patients were divided into two groups by PD-L1 expression:
a “PD-L1 positive” group and a “PD-L1 negative” group.
Statistical analysis
Statistical analysis was performed with SPSS software, ver-
sion 20.0 (SPSS, Chicago, IL, USA), MedCalc for Windows,
version 18.6.0.0 (MedCalc Software, Mariakerke, Belgium),
Figure 1 Patient selection diagram. CT, computed tomography; PD-L1, programmed death ligand 1.
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and R (version 3.6.0.; R Foundation for Statistical Comput-
ing, Vienna, Austria). Categorical variables are shown as
numbers with percentages. Continuous variables are pres-
ented as the mean  standard deviation. Demographics,
CT visual analysis results, and CT radiomic features were
compared between PD-L1 positive and PD-L1 negative
groups by chi-square test for categorical variables, and
independent t-test for continuous variables. Interobserver
Figure 2 CT images and radiomic analysis of a 34-year-old female with adenocarcinoma positive for PD-L1 expression. Axial (a) and coronal
(b) images of the initial contrast-enhanced CT scan show a 2.3 cm nodule in the left upper lobe which appears as a pure solid nodule with spicula-
tion and pleural attachment. Multiple metastatic left hilar, bilateral mediastinal and left supraclavicular lymph nodes are present. The patient was
diagnosed as having adenocarcinoma with high PD-L1 expression (tumor proportion score = 80%) and epidermal growth factor receptor wild-type
via ultrasound-guided neck lymph node biopsy. (c) Radiomic feature extraction was performed with segmentation of the volume of interest of the
left upper lobe nodule. The Rad-score is 1.350, which is higher than the cutoff value of −0.715 for positive PD-L1 expression. CT, computed tomog-
raphy; PD-L1, programmed death ligand 1.
996 Thoracic Cancer 11 (2020) 993–1004 © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd
Radiomics for PD-L1 expression in LA J. Yoon et al.
agreements were analyzed using the weighted kappa statis-
tic for qualitative CT features from visual analysis and the
intraclass correlation coefficient (ICC) for the lesion diam-
eter and CT radiomic features. Weighted kappa values
were interpreted as follows: poor, <0.2; fair, 0.2–0.4; mod-
erate, 0.4–0.6; good, 0.6–0.8; and excellent, >0.8. ICCs were
interpreted as follows: poor, <0.5; moderate, 0.5–0.75;
good, 0.75–0.9; excellent, >0.9. ICC values lower than zero
were considered zero for the analysis.
To diminish the high dimension of the radiomic features
to the number of events, we performed three sequential
steps for radiomic feature selection. At first, we evaluated
the interobserver agreement of radiomic features and
selected features showing ICC > 0.75. For the next step, we
chose radiomic features which showed statistical signifi-
cance between the PD-L1 positive and PD-L1 negative
groups. Finally, the least absolute shrinkage and selection
operator (LASSO) logistic regression model was used to
choose the most useful predictive features for PD-L1 posi-
tivity: three-fold cross validation was performed 100 times
to avoid the overfitting. Features showing nonzero coeffi-
cient were selected when the mean of the calculated area
under the receiver operating characteristic (ROC) curve
(AUC, predictive accuracy) of LASSO regression model
reached maximum among 100 times three-fold cross vali-
dations. A Rad-score (radiomic score) was calculated for
each case via a linear combination of selected features that
were weighted by their respective coefficient on the LASSO
logistic regression model.26
Continuous variables such as age and Rad-score were
dichotomized, and the optimal cutoff value to predict PD-
L1 positivity was calculated from the ROC curves using
Youden index. Univariate and multivariate logistic regres-
sion analyses were performed to assess the association
between clinical variables/CT visual analysis results/Rad-
score and PD-L1 positivity. We constructed two models for
multivariate logistic regression analysis (one based on the
clinical variables, and the other based on a combination of
clinical variables and imaging features) and compared c-
statistics of each model to identify the model with the higher
predictability. For internal validation of the result within the
study population, we performed bootstrap validation with
1000 resampling and optimism corrected AUC (c-index)
with 95% confidence interval (CI) was analyzed.27 A P-value
less than 0.05 less was considered statistically significant.
Results
Clinical characteristics of patients
Among 153 patients, 53 patients were classified as PD-L1
positive and 100 patients were classified as PD-L1 negative
(Table 1). There was no significant difference in clinical
characteristics including age, sex, smoking history, TNM
stage, and EGFR mutation status between the two PD-L1
expression groups (P > 0.05 for all).
Association between PD-L1 expression and
CT visual analysis
Among imaging findings which were analyzed by visual
analysis, none showed a significant difference between the
two PD-L1 expression groups (P > 0.05, Table 2).
Interobserver agreement for visual
analysis and radiomic features
Details of interobserver agreement for visual analysis are
presented in Table S2. Interobserver agreement for the






(n = 100) P-value
Age (mean  SD) 64.1  11.2 64.8  10.6 0.6916
Sex 0.9170
Male 34 (64.2) 65 (65.0)
Female 19 (35.8) 35 (35.0)
Smoking 0.9630
Current smoker 9 (17.0) 18 (18.0)
Past smoker 20 (37.7) 39 (39.0)
Never smoker 24 (45.3) 43 (43.0)
TNM stage 0.3830
3B 5 (9.4) 6 (6.0)
3C 3 (5.7) 1 (1.0)
4A 13 (24.5) 27 (27.0)
4B 32 (60.4) 65 (65.0)
4C 0 (0) 1 (1.0)
EGFR mutation 0.8061
Yes 18 (34.0) 32 (32.0)




Lung 22 (41.5) 55 (55.0)
Lymph node 23 (43.4) 34 (34.0)
Liver 2 (3.8) 3 (3.0)
Brain 3 (5.7) 4 (4.0)
Bone 3 (8.7) 3 (3.0)
Miscellaneous 0 (0) 1 (1.0)
Method of histopathologic
diagnosis (for lung lesion)
0.3089
CT-guide lung biopsy 6 (27.3) 24 (43.6)
Transbronchial lung biopsy 16 (72.7) 30 (54.5)
Video-assisted
thoracoscopic surgery
0 (0.0) 1 (1.8)
Unless otherwise indicated, data in parentheses are percentages. EGFR,
epidermal growth factor receptor; PD-L1, programmed death ligand 1;
SD, standard deviation.
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measurement of maximal and minimal diameters of tumor
was excellent (ICC 0.874 and 0.955, respectively). Most of
the 25 CT visual analysis features showed good to excellent
interobserver agreement (weighted kappa >0.6). Only
bubble-like lucency showed moderate interobserver agree-
ment (weighted kappa = 0.555).
Table 2 Comparison of computed tomography (CT) visual analysis results according to PD-L1 expression
PD-L1 expression
Positive (n = 53) Negative (n = 100) P-value
Maximal diameter of tumor (mm) (mean  SD) 48.1  19.7 44.5  23.2 0.710
Minimal diameter of tumor (mm) (mean  SD) 31.7  13.6 27.6  14.4 0.937
CT pattern 0.933
Solid predominant part-solid nodule 3 (5.7) 6 (6.0)
Pure solid nodule 33 (94.3) 94 (94.0)
Distribution 0.430
Central 22 (41.5) 35 (35.0)
Peripheral 31 (58.5) 65 (65.0)
Lobe location 0.535
Right upper lobe 16 (30.2) 23 (23.0)
Right middle lobe 4 (7.5) 4 (4.0)
Right lower lobe 12 (22.6) 25 (25.0)
Left upper lobe 9 (17.0) 27 (27.0)
Left lower lobe 12 (22.6) 21 (21.0)
Contour 0.678
Irregular 3 (5.7) 9 (9.0)
Round or oval 50 (94.3) 91 (91.0)
Lobulation 23 (43.4) 41 (41.0) 0.909
Concavity 47 (88.7) 93 (93.0) 0.544
Spiculation 34 (64.2) 75 (75.0) 0.221
Calcification 4 (7.5) 10 (10.0) 0.837
Air bronchogram 20 (37.7) 35 (35.0) 0.874
Bubble-like lucency 2 (3.8) 5 (5.0) >0.999
Fissure attachment 25 (47.2) 36 (36.0) 0.242
Pleural attachment 44 (83.0) 77 (77.0) 0.508
Thickened adjacent bronchovascular bundle 23 (44.2) 39 (39.0) 0.654
Pleural retraction 31 (58.5) 62 (62.0) 0.803
Peripheral emphysema 8 (15.1) 13 (13.0) 0.911
Cavitation 4 (7.5) 7 (7.0) >0.999
Necrosis 23 (43.4) 31 (31.0) 0.177
Pleural effusion 23 (43.4) 33 (33.0) 0.274
N stage 0.228
N0 2 (3.8) 10 (10.0)
N1 3 (5.7) 11 (11.0)
N2 14 (26.4) 17 (17.0)
N3 34 (64.2) 62 (62.0)
Lesion type 0.489
Mass 36 (67.9) 69 (69.0)
Nodule 15 (28.3) 28 (28.0)
Multicentric 0 (0.0) 2 (2.0)
Consolidation with GGO 2 (3.8) 1 (1.0)
Lung metastasis 0.313
No 36 (67.9) 53 (53.0)
Miliary (< 5 mm) 3 (5.7) 4 (4.0)
Scattered (≥ 5 mm) 6 (11.3) 24 (24.0)
Lymphangitic 5 (9.4) 13 (13.0)
Hematolymphangitic 3 (5.7) 6 (6.0)
Pleural nodularity 25 (47.2) 50 (50.0) 0.87
Significant pericardial effusion 9 (17.0) 9 (9.0) 0.232
Intrathoracic bone metastasis 14 (26.4) 37 (37.0) 0.254
Unless otherwise indicated, data in parentheses are percentages. CT, computed tomography; GGO, ground-glass opacity; SD, standard deviation.
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Table 3 Comparison of computed tomography (CT) radiomic features according to PD-L1 expression
PD-L1 expression
Positive (n = 53) Negative (n = 100) P-value
Histogram feature (mean  SD)
Texture_Histo_Mean (HU) 0.9  73.0 −1.4  78.2 0.861
Texture_Histo_SD (HU) 114.3  65.6 109.8  60.5 0.671
Texture_Histo_Skewness −2.5  1.9 −2.6  1.5 0.643
Texture_Histo_ExcessKurtosis 20.4  25.6 17.4  17.9 0.448
Texture_Histo_Energy 0.0070  0.0031 0.0063  0.0022 0.124
Texture_Histo_Entropy 7.9  0.7 7.9  0.6 0.567
Texture_Histo_Min (HU) −825.4  153.1 −807.4  159.3 0.499
Texture_Histo_Max (HU) 378.1  289.8 376.4  268.8 0.971
Texture_Histo_Voxel count 61 292.2  86 630.8 78 247.3  180 123.1 0.433
Percentile (mean  SD)
Texture_Percentile_10 (HU) −136.1  195.6 −133.1  185.1 0.926
Texture_Percentile_25 (HU) −26.8  107.9 −34.5  117.7 0.695
Texture_Percentile_50 (HU) 32.8  55.6 28.6  67.0 0.695
Texture_Percentile_75 (HU) 65.5  35.3 63.1  39.1 0.71
Texture_Percentile_90 (HU) 90.1  38.8 88.2  34.4 0.766
Texture_Percentile_95 (HU) 105.8  46.5 103.5  36.6 0.763
Gradient feature (mean  SD)
Texture_Grad_Mean 119.3  70.4 121.6  70.1 0.848
Texture_Grad_SD 124.9  39.4 122.5  38.0 0.714
GLCM feature (mean  SD)
Texture_GLCM_ASM 0.0737  0.0478 0.0582  0.0331 0.038
Texture_GLCM_IDM 0.5  0.1 0.5  0.1 0.243
Texture_GLCM_Homogeneity 0.6  0.1 0.6  0.1 0.242
Texture_GLCM_Contrast 9.2  10.6 8.6  9.0 0.744
Texture_GLCM_Correlation 0.6  0.2 0.6  0.1 0.985
Texture_GLCM_Autocor 1094.4  120.4 1090.8  128.5 0.868
Texture_GLCM_Entropy 5.3  1.4 5.4  1.1 0.497
Texture_GLCM_CP 48 607.0  148 803.9 32 033.0  87 988.2 0.459
Texture_GLCM_CS −1028.0  2715.2 −750.4  1673.0 0.499
Texture_GLCM_CT 51.5  87.7 44.5  67.1 0.612
Texture_GLCM_SumEntropy 3.7  0.8 3.7  0.7 0.635
Texture_GLCM_DiffAverage, 1.7  1.0 1.7  0.9 0.925
Texture_GLCM_DiffEntropy 2.3  0.6 2.3  0.5 0.721
GLRLM feature (mean  SD)
Texture_GLRLM_SRE 0.0494  0.0285 0.0347  0.0229 0.001
Texture_GLRLM_LRE 0.5  0.6 0.2  0.3 0.002
Texture_GLRLM_LGRE 0.0003  0.0012 0.0001  0.0008 0.471
Texture_GLRLM_HGRE 89.1  59.2 57.6  42.3 0.001
Texture_GLRLM_SRLGE 0.0002  0.0007 0.0001  0.0005 0.485
Texture_GLRLM_SRHGE 56.8  33.8 39.7  26.8 0.002
Texture_GLRLM_LRLGE 0.0020  0.0106 0.0008  0.0058 0.454
Texture_GLRLM_LRHGE 604.0  722.4 266.7  319.9 0.002
Texture_GLRLM_GNUN 0.0034  0.0044 0.0013  0.0020 0.002
Texture_GLRLM_RLNUN 0.0031  0.0030 0.0016  0.0019 0.001
Texture_GLRLM_RP 0.0771  0.0503 0.0501  0.0360 0.001
Texture_GLRLM_RV 0.4  0.5 0.2  0.2 0.002
Texture_GLRLM_RE 0.5  0.3 0.4  0.2 0.001
Moment feature (mean  SD)
Texture_Moment_J1 29.0  46.4 32.9  67.6 0.669
Texture_Moment_J2 0.0007  0.0022 0.0015  0.0054 0.221
Texture_Moment_J3 <0.0001  <0.0001 <0.0001  <0.0001 0.203
Shape feature (mean  SD)
Shape_Volume (mm3) 43 718.0  53 318.6 51 640.9  114 615.3 0.561
Shape_SurfaceArea (mm2) 11 496.3  10 465.8 12 840.4  15 782.6 0.530
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Most of the 58 radiomic features showed good to
excellent interobserver agreement (ICC > 0.75). Texture_His-
to_Skewness and Texture_GLRLM_RLNUN (run-length
nonuniformity normalized of GLRLM) showed moderate
interobserver agreement (ICC 0.5–0.75). Details of the ICCs
for all radiomic features are described in Table S3.
Selection of CT radiomic features
Among CT radiomic features, Texture_GLCM_ASM (angu-
lar second momentum of GLCM) and most of GLRLM fea-
tures showed significant differences between PD-L1 positive
and PD-L1 negative groups (P < 0.05 for all, Table 3). No
other CT radiomic feature was significantly different
between the two PD-L1 expression groups (P > 0.05).
After feature selection processes, selected radiomics feature
sets were as follows: Texture_GLCM_ASM, Texture_
GLRLM_RV (run variance of GLRLM), Texture_GLRLM_RE
(run entropy of GLRLM), Texture_GLRLM_SRHGE (short-
run high gray-level emphasis of GLRLM). The radiomics sig-
nature was computed into a Rad-score by using the following
formula:
Rad-score = −(1.594 23) + Texture_GLCM_ASM x
− 8.495 68 + Texture_GLRLM_RV x 3.585 97 + Texture_
GLRLM_RE x (−5.01416) + Texture_GLRLM_SRHGE x
0.05253.
The Rad-score was higher in the PD-L1 positive group
than in the PD-L1 negative group with a statistical signifi-
cance (−0.378  1.537 vs. −1.171  0.822, P = 0.0008). The
AUC of Rad-score to predict PD-L1 positivity was 0.661
(95% CI 0.580–0.735) and the optimum cutoff value
calculated from the ROC curves was −0.715 (sensitivity
52.8%, specificity 76.0%). In patients with EGFR wild-type
tumor, the Rad-score was higher in the PD-L1 positive group
than in the PD-L1 negative group with a statistical signifi-
cance (−0.419  1.578 vs. −1.135  0.861, P = 0.0162).
Prediction model for PD-L1 positivity
In univariate logistic regression analysis, a Rad-score >
−0.715 showed significant association with PD-L1 status
(odds ratio [OR] 3.3600; 95% CI 1.6617–6.7940; P = 0.0007;
c-statistic 0.639 [95% CI 0.558–0.715]; Table 4). None of the
clinical variables or qualitative imaging features showed a
significant association with PD-L1 status (P > 0.05).
We established two prediction models for predicting
PD-L1 positivity: model 1 uses clinical variables and model
2 uses clinical variables and CT radiomic features. The pre-
dictive performance was higher with model 2 (c-
Table 3 Continued
PD-L1 expression
Positive (n = 53) Negative (n = 100) P-value
Shape_Sphericity 0.5  0.1 0.5  0.1 0.417
Shape_Compactness 1.0  0.0 0.9  0.0 0.426
Shape_Roundness 0.7  0.1 0.7  0.1 0.089
Shape_Circularity 0.4  0.1 0.3  0.1 0.442
Shape_Longest1stAxis (mm) 54.2  22.4 57.8  30.9 0.408
Shape_Longest2ndAxis (mm) 44.0  19.1 45.3  23.1 0.726
Shape_PCA1stMajorSD (mm) 11.3  4.7 11.7  6.3 0.626
Shape_PCA2ndMajorSD (mm) 8.6  3.6 8.7  4.3 0.823
Shape_PCA3rdMajorSD (mm) 7.1  3.0 7.0  3.6 0.779
Fractal feature (mean  SD)
Fractal dimension 2.4  0.2 2.4  0.2 0.626
Unless otherwise indicated, data in parentheses are percentages. ASM, angular second moment; Autocor, autocorrelation; CP, cluster prominence;
CS, cluster shade; CT, cluster tendency; GLCM, gray-level co-occurrence matrix; GLRLM, gray-level run-length matrix; GNUN, gray-level non-
uniformity normalized; Grad, gradient; HGRE, high gray-level run emphasis; Histo, histogram; HU, Hounsfield Unit; IDM, inverse different moment;
LGRE, low gray-level run emphasis; LRE, long run emphasis; LRHGE, long run high gray-level emphasis; LRLGE, long run low gray-level emphasis;
Max, Maximum; Min, minimum; PCA, principal component analysis; PD-L1 = programmed death ligand 1; RE, run entropy; RLNUN, run-length non-
uniformity normalized; RP, run percentage; RV, run variance; SD, standard deviation; SRE, short run emphasis; SRHGE, short run high gray-level
emphasis; SRLGE, short run low gray-level emphasis.
Table 4 Univariate logistic regression analysis for prediction of PD-L1
positivity
Clinical variables OR (95% CI) P-value
Age (≤59 years) 0.7299 (0.3480–1.5266 0.4017
Female sex 1.0378 (0.5176–2.0810) 0.9167
Current or ex-smoker 0.9512 (0.4841–1.8690) 0.8845
Presence of EGFR mutation 1.0929 (0.5390–2.2160) 0.8055
Rad-score
Rad-score > −0.715 3.3600 (1.6617–6.7940) 0.0007
CI, confidence interval; EGFR, epidermal growth factor receptor; OR,
odds ratio; PD-L1, programmed death ligand 1.
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statistic = 0.667; 95% CI = 0.575–0.760) than model 1 (c-
statistic = 0.550; 95% CI = 0.454–0.646), with a statistical
significance (P = 0.0299, Table 5). The c-statistics in the
development set were similar to the values with bootstrap
estimates in the internal validation, with significant differ-
ence between two models (difference of c-statistics between
two models, 0.117, 95% CI = 0.012–0.225).
Discussion
Our study demonstrates that quantitative radiomic features
can help predict PD-L1 expression in advanced lung ade-
nocarcinoma, whereas none of the qualitative imaging
findings is associated with PD-L1 positivity. Furthermore,
a prediction model constructed with Rad-score in combi-
nation with clinical variables shows a higher c-statistic than
a model constructed with clinical variables only.
Since PD-L1 has been expected to predict the response of
immune checkpoint inhibitors in lung cancer patients,8–10
there were few previous studies that attempted to predict
PD-L1 expression noninvasively in surgically resected lung
adenocarcinomas using imaging modalities.12,13,28 Previous
studies reported that qualitative CT features such as lobular/
irregular shape, pleural indentation, presence of conver-
gence/cavitation, absence of surrounding GGO/air-broncho-
gram, and quantitative CT imaging features such as mean
CT attenuation of tumor, higher consolidation to tumor
mass ratio (C/T ratio), and higher maximum standardized
uptake value on positron emission tomography were signifi-
cantly associated with PD-L1 positivity.12,13,28
According to previous studies regarding imaging features
of PD-L1-positive NSCLCs, a large solid portion with a
small GGO on CT scan was a common feature associated
with PD-L1 expression, which can be explained by a corre-
lation with pathological invasiveness, histologic subtype, or
proportion of EGFR mutation.12,13,28 In surgically-resected
lung adenocarcinomas, tumors with PD-L1 expression
tended to be more invasive histologic subtypes with a worse
prognosis (e.g., solid predominant) than tumors without
PD-L1 expression.12,13,28,29 Because GGO in subsolid nodules
is thought to correlate with the lepidic component of lung
adenocarcinomas, lung adenocarcinomas with preinvasive
or lepidic predominant subtypes mostly present as pure
ground-glass nodules or part-solid nodules on CT, whereas
lung adenocarcinomas with micropapillary or solid pre-
dominant subtypes present as pure solid nodules.30–34
Meanwhile, NSCLCs with EGFR mutations tended to have
higher GGO proportions on CT,31,34–38 which might be
explained by the fact that they have a high prevalence of
lepidic-predominant histologic types.31,39–43 The presence of
an EGFR mutation was thought to be inversely correlated
with PD-L1 expression in NSCLCs,44 although there have
been controversies, and the relationship was not statistically
significant in our study. Therefore, a large solid portion
with a small GGO on CT in a PD-L1 positive adenocarci-
noma might demonstrate the relationship between CT find-
ings with histologic subtype, and also with EGFR mutation.
Other qualitative CT features including lobular/irregular
shape, presence of convergence/cavitation, and pleural inden-
tation have been suggested as predictive imaging features of
PD-L1 positivity and were also supposed to be associated
with the pathological invasiveness of the tumor. However, in
our study, none of the qualitative imaging features on visual
analysis was related to PD-L1 positivity. This result may be
due to differences in the clinical characteristics of our study
population compared to those in previous studies. Previous
studies also included patients with surgically resected lung
adenocarcinomas, the majority of which were early stage,
resectable cases.12,13,28 On the other hand, our study included
patients with unresectable adenocarcinomas, who could be
better candidates for immunotherapy than patients with
early stage tumors.45 Therefore, the results of our study may
have more clinical value than those of previous studies.
Although interest in quantitative imaging biomarker is
increasing, the application of radiomics in thoracic oncol-
ogy has been limited to prediction of EGFR mutation or
Table 5 Multivariate logistic regression models for prediction of PD-L1 positivity
OR 95% CI P-value OR 95% CI P-value
Model 1 (clinical variables) Model 2 (clinical variables + CT radiomic features)
Age ≤ 59 years 0.7281 0.3362–1.5232 0.408 0.6106 0.2691–1.3259 0.2227
Female sex 1.0820 0.3793–3.1603 0.883 0.9354 0.3121–2.8772 0.9053
Current or ex-smoker 1.0635 0.3823–3.1009 0.907 0.9115 0.3129–2.7532 0.8658
Presence of EGFR mutation 1.1710 0.5272–2.5799 0.695 1.1098 0.4821–2.5304 0.8042
Rad-score > −0.715 N/A N/A N/A 3.4706 1.6919–7.2840 0.0008






0.550 (0.461–0.6488) 0.667 (0.577–0.764)
CI, confidence interval; EGFR, epidermal growth factor receptor; OR, odds ratio; PD-L1, programmed death ligand 1.
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survival after treatment.14–19 Our study suggests that adding
radiomic features to clinical variables could increase pre-
dictability for PD-L1 expression in advanced lung adeno-
carcinomas, and to our knowledge, this was the first
attempt to investigate the value of radiomic features for
prediction of PD-L1 expression.
In our study, four radiomic features (Texture_
GLCM_ASM, Texture_GLRLM_RV, Texture_GLRLM_RE,
Texture_GLRLM_SRHGE) were selected. Texture_GLCM_
ASM is a measure of homogenous patterns in the image, and
GLRLM quantifies gray level runs, which are defined as the
length of consecutive voxels that have the same gray level
value. Since the Rad-scores in our study demonstrated a ten-
dency for larger Texture_GLCM_ASM, Texture_GLRLM_
RV and Texture_GLRLM_SRHGE with smaller Texture_
GLRLM_RE being correlated with PD-L1 expression, the
lesion with homogenous and high CT attenuating large voxel
values could be more likely to be PD-L1-positive. In other
words, a homogenous tumor presenting as a pure solid nod-
ule with no or small GGO, inner necrosis, cavitation, or calci-
fication may have PD-L1 positivity in advanced lung
adenocarcinoma, which was similar to the results of previous
studies of early stage lung adenocarcinomas, even though the
trend was not clearly seen on visual analysis in our study.
This study had several limitations. First, it was con-
ducted retrospectively from a single tertiary referral center,
and patients were identified only from those having PD-L1
testing results, which can lead to a selection bias. Second,
the proposed prediction model did not undergo external
validation in other cohorts, therefore, our findings might
be difficult to generalize. Third, the PD-L1 test lacks uni-
versal reference standards, and among several testing
methods for confirming PD-L1 positivity,46 PD-L1 immu-
nohistochemistry was conducted with only two antibodies
and one cutoff value. Finally, the treatment response after
immunotherapy was not assessed. Further studies are
needed to evaluate the predictive value of CT radiomic fea-
tures for treatment response after anti-PD-L1 therapy.
In conclusion, quantitative CT radiomic features can
predict PD-L1 expression in advanced stage lung adenocar-
cinoma. Furthermore, a prediction model composed of
clinical variables and CT radiomic features may facilitate
noninvasive assessment of PD-L1 expression.
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